Tower Research Capital (TRC)’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-81	Closed	-$1K	–	3631
2016 Q2	$1K	Sell	81 -100	-55%	-$1.96K	﹤0.01%	4121
2016 Q1	$3K	Sell	181 -215	-54%	-$4.17K	﹤0.01%	3047
2015 Q4	$12K	Sell	396 -254	-39%	-$7.34K	﹤0.01%	1866
2015 Q3	$17K	Buy	650 +646	+16,150%	+$21.9K	﹤0.01%	1865
2015 Q2	$0	Sell	4 -1,566	-100%	-$53.8K	﹤0.01%	4374
2015 Q1	$52K	Buy	1,570 +1,540	+5,133%	+$47K	0.01%	1430
2014 Q4	$1K	Buy	+30	New	+$822	﹤0.01%	3591

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

MFS

MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Tower Research Capital (TRC)'s BBC Position: Q3 2016 in Review

Tower Research Capital (TRC) sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2016, closing a stake of 81 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in BBC in Q4 2014 and held it in 7 quarters. The position peaked at $52K in Q1 2015. 13 funds tracked by Wall St. Rank hold BBC as of Q3 2016.

Tower Research Capital (TRC) reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 81 Virtus Biotech Clinical Trials ETF shares in Q3 2016, an estimated $1K.
Tower Research Capital (TRC) first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2014 and held it in 7 quarters.
Tower Research Capital (TRC)'s Virtus Biotech Clinical Trials ETF position peaked at $52K in Q1 2015.
13 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2016, filed 8 Nov 2016.